Financing - June 23, 2016
Immunicum raises approx SEK 128 million in oversubscribed rights issue
Immunicum’s rights issue of approximately SEK 111 million, which ended on June 14, 2016, was oversubscribed. In view of the strong demand from both new and existing shareholders the over-allotment option has been exercises in part, amounting to approximately SEK 17 million. Immunicum’s proceeds of the issue thereby totaled approximately SEK 128 million before transaction costs. Immunicum’s extra general meeting, […]
Financing - March 9, 2016
Aprea raises SEK 437 million
Karolinska Development’s portfolio company Aprea has raised SEK 437 million ($51 million) in a Series B financing round – the largest private financing to date by one of its portfolio companies, and more broadly by any private life science company in Sweden in the last decade. The syndicate was co-led by specialist life sciences investors […]
Financing - February 2, 2016
Vaccibody granted NOK 20 million
Vaccibody has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour- specific mutations in cancer cells. While most commonly shared tumour antigens used in cancer vaccines to date […]
Financing - January 13, 2016
Dynamic Code receives SEK 3 million from VINNOVA
Swedish Dynamic Code, developing DNA tests, has been givinga SEK 3 million funding from Vinnova. According to the company, the money will be spent on developing a new overall plan for future health tests simply used at home. The project goes under the name Dynamichealthcare.se. At the site customers will be offered different health tests […]
Financing - May 7, 2015
Medivir Bd. to Repurchase Shares
Medivir AB’s board of directors plans to use the authorization given at the annual general meeting to repurchase class B company shares. The repurchases will be carried out in batches over time, but will conclude prior to the next annual general meeting. The execution of the repurchases will depend on market conditions, according to BioSpace.com, […]
Financing - April 2, 2015
NEA Raising Investment Money
One of the largest venture capital players in the world, New Enterprise Associates (NEA), has raised $3.51 billion for two new “opportunities” funds, with as much as $900 million possibly becoming invested in the biotech sector, BioScience.com notes. The two new NEA vehicles surpass the industry standard setting $3 billion fund that Technology Crossover Ventures […]
